SARA VANLANINGHAM: Open Payments
NPI 1013469659 · WARSAW, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$297 in 16 payments from 11 companies in 2025. Trend: 2023 $259 · 2024 $436 · 2025 $297
Food & beverage: $297
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $68 |
| ABBVIE INC. | 2 | $46 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $41 |
| Dexcom, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Exact Sciences Corporation | 1 | $17 |
| Antares Pharma, Inc. | 1 | $14 |
Products named: QULIPTA, Kerendia, Ozempic, Wegovy, Dexcom G6 Transmitter, Veozah, REXULTI, CAPLYTA.
Industry payments across IN — which companies pay providers there.
